AE Risk Examined for Abiraterone, Enzalutamide in Prostate Cancer
Risk for metabolic or cardiovascular adverse events increased for men receiving abiraterone or enzalutamide for advanced disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.